The global protein A resins market is slated to reach USD 677.84 million in 2023. According to Future Market Insights' recent study, the market is projected to attain USD 1,477.01 million by 2033. From 2023 to 2033, the market is expected to register a CAGR of 8.1%.
In terms of product, the market has been bifurcated between natural protein A resin and recombinant protein A resin. FMI has forecast the demand for natural protein A resin to account for maximum sales in the protein A resin market through the assessment period.
| Data Points | Market Insights |
|---|---|
| Protein A Resins Market Value 2023 | USD 677.84 million |
| Protein A Resins Market Value 2033 | USD 1,477.01 million |
| Protein A Resins Market CAGR 2023 to 2033 | 8.1% |
| Key Players |
Repligen; Danaher (Cytiva Lifesciences); Merck Millipore; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific Inc.; Perkinelmer, Inc |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increasing production of monoclonal antibodies in contract manufacturing organizations is expected to drive revenue growth for the overall protein A resins market over the forecast period. The trend for manufacturing biologics in CMOs started in the 1980s. Over the last few years, the trend in CMOs has changed drastically, shifting from manufacturing blockbuster drugs to specialist care drugs, including monoclonal antibodies.
Very few companies have in-house manufacturing capabilities. The management of the supply chain adds to the complexity of manufacturing processes. The establishment of such high-containment biologic facilities requires higher investment, which can be a great financial risk. Thus, contract manufacturing organizations (CMOs) are outsourced to develop and produce monoclonal antibodies, driven by the increasing need for biotechnology companies that require unique development expertise and facilities.
Contract manufacturing organizations are expected to play an important role in the production of active pharmaceutical ingredients and biologics, including monoclonal antibodies, thereby opening up new revenue pockets in the protein A resins.
The increasing prevalence of cancer is expected to increase the production of monoclonal antibodies for use in therapeutic areas. The potential application of monoclonal antibodies in diagnosing and treating various cancer types has been widely accepted. Each cancer type requires a unique treatment. Thus, it is expected to provide opportunities for market players by driving sales of protein A resin over the forecast period.
Increasing the use of monoclonal antibodies in various therapeutic areas owing to their flexibility and specificity and the need for protein A resin is expected to drive the sales of protein A resins over the forecast period.
Many pharmaceutical and biotechnological companies are researching and developing (R&D) on monoclonal antibodies to find new therapeutic areas. Companies are already manufacturing monoclonal antibody products for therapeutic areas such as cardiovascular, immune therapy, microbial infections, inflammatory disorders, Crohn's disease, transplants, and certain types of cancer such as leukemia and breast cancer.
The biologics segment in the life sciences industry has gained acceptance by biotechnology and other research institutes for their areas of research, as it has shown promising results as well as low side effects in the treatment of different diseases, such as cancer, autoimmune diseases, and certain genetic conditions.
Biologic therapies, being more target-mediated than non-biologic treatments, are also used as a first-line treatment in some cancer cases. Biologics is the fastest-growing segment in the healthcare industry, with monoclonal antibodies being the key product.
The growing biologics segment is thus expected to offer lucrative growth opportunities for protein A resin manufacturers in the near future.
Principal Consultant
According to Future Market Insights (FMI), the sales of protein A resins have grown at a CAGR of nearly 4.8% between 2018 and 2022. Increasing research on monoclonal antibodies (mAbs), CMO's role in mAbs manufacturing, wide therapeutic application of mAbs, production of next-generation protein A resins overcoming ligand leaching issues, and favorable government policies and funding are expected to drive the sales of protein A resins and also provides a positive impetus on the market growth.
Manufacturers are financing research and development activities to come about advanced protein A chromatography resins or their alternatives to address the high cost and operational bottlenecks associated with it. Followed by mergers, acquisitions, collaborations, and product launches through extensive research and development for strengthening product portfolios are the key strategies adopted by manufacturers to increase their revenue. Adopting these strategies helped the companies spread their regional presence and diversify their product offerings.
For instance, in September 2021, Purolite Life Sciences announced the commercialization of two novel next-generation chromatography resins, Praesto Jetted A50 HipH, and Praesto® Jetted (dT)18-DVB, in association with Repligen.
In June 2021, Thermo Fisher Scientific Inc. collaborated with Newomics, a commercial-stage biotechnology company, to develop a novel native liquid chromatography-mass spectrometry (LC−MS) platform which can support various LC−MS applications. The agreement is expected to help improve the throughput and robustness of microflow LC-MS in proteomics and biopharmaceutical applications.
Future Market Insights expects the protein A resins market to register a CAGR of 8.1% by the end of 2033. The growth is attributed to the rise in research and development activities for innovative technology development. Leading companies actively participate in approval, partnership, collaboration, merger, and acquisitions to expand their market presence and strengthen product portfolios.
| Historical CAGR (2018 to 2022) | 4.8% |
|---|---|
| Forecast CAGR % (2023 to 2033) | 8.1% |
In 2023, the United States is assessed to account for more than 93.5% value share in North America. The demand for protein A resin is increasing in the United States due to the rise in biopharmaceutical companies focusing on developing and commercializing biosimilar drugs in the region. Besides this, improvement in the quality control systems is anticipated to continue augmenting growth in North America.
The United Kingdom is expected to account for nearly 24.1% of the market in Europe by 2033. The rise in demand for protein A resins in the United Kingdom is primarily due to the increasing requirement for protein therapeutics for the treatment of chronic diseases, the presence of well-established biotechnology and pharmaceutical companies, and rising government funding. Furthermore, a favorable regulatory scenario is likely to offer up new opportunities for the protein A resins market in the United Kingdom.
| Country | China |
|---|---|
| Market CAGR % (2023 to 2033) | 9.8% |
The China market is expected to register a 9.8% CAGRin the East Asia market through the forecast period. The increasing use of biomaterials in drug research, adoption of advanced technologies to leverage healthcare research, expansion of the pharmaceutical industry, and the rising need for vaccines and other therapeutics are the key factors driving the growth in China.
Favorable government policies and growing funding for the expansion of healthcare infrastructure are expected to create a conducive environment for growth in China.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Segment | Natural Protein A Resins |
|---|---|
| Market Share % (2023) | 62.8% |
In terms of products, natural protein A resins are expected to capture a maximum market share of 62.8% in 2023. Natural protein A is extracted from a staphylococcus aureus species’ bacterial cell. It is primarily utilized in the cleansing of monoclonal antibodies. It helps in minimizing ligand leaching and stability issues of traditional protein A resins.
| Segment | Agarose-based Matrix |
|---|---|
| Market Share % (2023) | 85.8% |
In terms of a matrix, the agarose-based matrix of protein A resins is expected to enjoy a market share of 85.8% in 2023, indicating a significant demand in the market. Agarose-based matrix offers high binding specificity when compared with other matrices and are, therefore, extensively used to attach ligands that stick proteins. The running trend is expected to continue, yielding growth in the segment through the forecast period.
| Segment | Antibody Purification |
|---|---|
| Market Share % (2023) | 74.8% |
By application, the antibody purification of protein A resins segments is expected to account for 74.8% of the market share in 2023. Sales in the segment are primarily steered by demand from large-scale industries like biopharmaceuticals to isolate monoclonal antibodies.
| Segment | Biopharmaceutical Manufacturers |
|---|---|
| Market Share % (2023) | 79.2% |
The biopharmaceutical manufacturers are expected to record 79.2% of the market share in 2023. The rising demand for protein engineering with various advancements and harnessing new scientific advances is likely to fuel demand in the segment.
Companies operating in the protein A resins market are taking proactive measures to invigorate their position via approval, collaborations, merger & acquisition partnerships, and agreements with established as well as emerging market players. The product launch and acquisition accelerate the manufacturer’s plan to capitalize on the market share and seize a significant share of the market. Some recent instances include:
| Attributes | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD million/ billion for Value |
| Key Countries Covered | The United States, Canada, Germany, The United Kingdom, France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, South Africa |
| Key Segments Covered | Product, Matrix, Application, End User, and Region |
| Key Companies Profiled | GE Healthcare; Thermo Fisher Scientific; Kaneka Corporation; JNC Corporation; Purolite Life Sciences; Bio-Rad Laboratories, Inc.; JSR Corporation (JSR Life Sciences LLC); Repligen; Tosoh Bioscience, Merck Group (Merck Millipore); Novasep Holdings SAS, Agilent Technologies, Inc.; GenScript, Abcam PLC (Expedeon Ltd.); Avantor Inc.; Takara Bio, PerkinElmer, Inc.; Suzhou Nanomicro Technology Co., Ltd |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
As of 2023, the global market size could stand at USD 677.84 million.
The global demand for Protein A Resins could witness 8.1% CAGR through 2033.
The overall segment is expected to account for 62.8% of the global market in 2023.
The regional market is forecasted to account for 93.5% of North America Market.
China market is poised to follow an impressive 9.8% CAGR up to 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Natural Protein A Resin 5.2. Recombinant Protein A Resin 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Matrix 6.1. Agarose Based Matrix 6.2. Glass or Silica Based Matrix 6.3. Organic Polymer Based Matrix 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 7.1. Immunoprecipitation 7.2. Antibody Purification 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 8.1. Biopharmaceutical Manufacturers 8.2. Clinical Research Laboratories 8.3. Academic Institutes 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. South Asia and Pacific 9.6. East Asia 9.7. Middle East and Africa 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. GE Healthcare 19.2. Thermo Fisher Scientific 19.3. Kaneka Corporation 19.4. JNC Corporation 19.5. Purolite Life Sciences 19.6. Bio-Rad Laboratories, Inc. 19.7. JSR Corporation (JSR Life Sciences LLC) 19.8. Repligen 19.9. Tosoh Bioscience, Merck Group (Merck Millipore) 19.10. Novasep Holdings SAS, Agilent Technologies, Inc. 19.11. GenScript, Abcam PLC (Expedeon Ltd.) 19.12. Avantor Inc. 19.13. Takara Bio, PerkinElmer, Inc. 19.14. Suzhou Nanomicro Technology Co., Ltd 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Protein A Resins Market
